Nexo Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nexo Therapeutics, Inc. - overview
Established
2022
Location
Littleton, CO, US
Primary Industry
Biotechnology
About
Based in Colorado, US, and founded in 2022 by its CEO, Andrew Phillips, and co-founders Michael Kim, John Athanasopoulos, and Rhamy Zeid, Nexo Therapeutics, Inc. operates as a biotechnology company that is dedicated to developing drugs to target some cancer proteins. In July 2023, Nexo Therapeutics, Inc. raised USD 60 million in series A funding led by Versant Ventures, with participation from New Enterprise Associates and Cormorant Asset Management.
Nexo Therapeutics, Inc. develops cutting-edge drugs that directly address elusive proteins associated with various types of cancer. Its CODON (Covalent Discovery and Optimization) platform combines chemical diversity and covalent chemistry within a scalable framework of biochemical and in-cell proteomics. The company plans to use the series A funding to uncover a pipeline of cancer medicines directed against formerly impenetrable targets.
Current Investors
New Enterprise Associates, Versant Ventures, Cormorant Asset Management
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Oncology/Cancer Treatment
Website
www.nexotx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.